Q-omics provides the consensus-scored PGM5P2 profile across patient tissues and cancer cell-line models. PGM5P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PGM5P2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PGM5P2 RNA expression shows 20,632 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where PGM5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGM5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGM5P2 survival associations across molecular data types. PGM5P2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGM5P2 RNA expression–survival associations across cancer types. High PGM5P2 expression shows unfavorable associations in ACC and LGG, but favorable associations in BRCA, UCS, HNSC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PGM5P2 RNA expression.
This table summarizes PGM5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PGM5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGM5P2 shows lower tumor expression in KIRC, UCEC, BRCA, LUSC and KICH and higher tumor expression in CHOL. The KIRC box plot shows higher PGM5P2 RNA expression in normal versus tumor tissue (log2 FC = −0.398, t-test p < 0.001).
This table shows molecular features associated with PGM5P2 in patient tissues and cancer cell lines. In patient samples, PGM5P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PGM5P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
